Treatments and translation
A dated research summary covering investigational gene therapy work, supportive care areas, and the translational data needed for future studies. This is not a treatment recommendation or medical guidance.
Data last updated: May 8, 2026
Investigational
An investigational AAV9 gene therapy for IRF2BPL-related NEDAMSS has reached an individual first-in-human use case. Public materials describe a vector-based approach intended to deliver a functional IRF2BPL coding sequence, not an approved treatment and not an edit that removes the person's original gene. Open questions remain around eligibility, timing, dosing, route, safety follow-up, manufacturing, and regulatory access.
Supportive and research-stage
Published and family-reported care currently centers on seizure management, movement-disorder care, feeding and sleep support, rehabilitation, communication supports, and multidisciplinary neurology follow-up. Disease-modifying pharmacology remains research-stage.
Needed for future trials
Cohort definition, longitudinal outcome measures, and variant-level evidence are still central constraints for any future clinical program in this ultra-rare disorder.
April 2026 · Gene therapy update
In 2025, public updates from Elly's Team and RTW Foundation reported that a first child received an investigational AAV9 gene therapy for IRF2BPL-related NEDAMSS after FDA clearance of an IND for a single-patient treatment. The public materials describe a vector-based approach intended to deliver a functional IRF2BPL coding sequence; this site avoids shorthand that implies the original gene was swapped out, because AAV approaches generally add delivered genetic material rather than editing out the person's original gene. The treatment remains investigational and is not an approved, broadly available therapy.
Ongoing · Natural history and trial readiness
For NEDAMSS, trial readiness is not only about finding more patients. Researchers still need longitudinal data on when regression, seizures, movement symptoms, feeding issues, vision findings, MRI changes, and communication loss appear or progress; variant-level patterns that may affect severity; practical outcome measures that can detect stabilization or slowing; and biospecimens or model systems that connect IRF2BPL variants to mechanism. The completed Cincinnati Children's registry and the GeneReviews summary are useful anchors, but broader treatment planning still depends on continued family and clinician participation.